Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Deficient Mismatch Repair”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT05239741
What this trial is testing

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

Who this might be right for
Colorectal Neoplasms
Merck Sharp & Dohme LLC 100
Testing effectiveness (Phase 2)Study completedNCT03241745
What this trial is testing

Nivolumab in Selected Uterine Cancer Patients

Who this might be right for
Uterine CancerEndometrial CarcinomaCarcinosarcoma+4 more
Memorial Sloan Kettering Cancer Center 35
Early research (Phase 1)Study completedNCT03652077
What this trial is testing

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Who this might be right for
Cervical CancerGastric CancerStomach Cancer+18 more
Incyte Corporation 40
Testing effectiveness (Phase 2)WithdrawnNCT05419817
What this trial is testing

Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

Who this might be right for
Recurrent Endometrial CancerSolid Tumors
Haider Mahdi
Not applicableStudy completedNCT03047226
What this trial is testing

Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Colorectal Cancer

Who this might be right for
Lynch Syndrome
Second Affiliated Hospital, Zhejiang University, School of Medicine 311
Testing effectiveness (Phase 2)Ended earlyNCT04393454
What this trial is testing

Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy

Who this might be right for
Metastatic dMMR Solid CancerSolid TumorCancer+1 more
Albert Einstein College of Medicine 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT05200559
What this trial is testing

T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors

Who this might be right for
Epithelial Ovarian Cancer
Alexander B Olawaiye, MD 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT04006262
What this trial is testing

Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.

Who this might be right for
Localized Oesogastric AdenocarcimonaMSI and or dMMR
GERCOR - Multidisciplinary Oncology Cooperative Group 32
Not applicableNot Yet RecruitingNCT07780305
What this trial is testing

ABCSG R07 Rectal Cancer Registry

Who this might be right for
Rectal CancerAdenocarcinoma of Rectum
Austrian Breast & Colorectal Cancer Study Group 600
Large-scale testing (Phase 3)Active Not RecruitingNCT04008030
What this trial is testing

Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

Who this might be right for
Metastatic Colorectal Cancer
Bristol-Myers Squibb 839
Testing effectiveness (Phase 2)UnknownNCT05371197
What this trial is testing

Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer

Who this might be right for
Colorectal CancerMismatch Repair-deficient (dMMR)Microsatellite Instability-high (MSI-H)+1 more
Third Affiliated Hospital, Sun Yat-Sen University 26
Early research (Phase 1)WithdrawnNCT04500548
What this trial is testing

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Who this might be right for
Constitutional Mismatch Repair Deficiency SyndromeHematopoietic and Lymphoid Cell NeoplasmLynch Syndrome+9 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Looking for participantsNCT03736889
What this trial is testing

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

Who this might be right for
MSI-H/dMMR Solid Tumors
BeiGene 200
Testing effectiveness (Phase 2)Temporarily pausedNCT06250036
What this trial is testing

Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer

Who this might be right for
Locally Advanced Gastric AdenocarcinomaMSI-H/dMMR Gastric CancerMSI-H/dMMR Gastroesophageal-junction Cancer
Royal Marsden NHS Foundation Trust 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT02983578
What this trial is testing

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Who this might be right for
Advanced Colorectal CarcinomaAdvanced Lung Non-Small Cell CarcinomaLung Non-Small Cell Carcinoma+22 more
M.D. Anderson Cancer Center 39
Testing effectiveness (Phase 2)Study completedNCT03435107
What this trial is testing

Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Asan Medical Center 33
Testing effectiveness (Phase 2)Looking for participantsNCT05729646
What this trial is testing

Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Who this might be right for
Adenocarcinoma of the StomachAdenocarcinoma of Esophagogastric JunctionMismatch Repair Deficiency
Yu jiren 90
Testing effectiveness (Phase 2)Looking for participantsNCT05795244
What this trial is testing

Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)

Who this might be right for
Endometrial NeoplasmsEndometrial Cancer
Yonsei University 30